ADMA Biologics (ADMA) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• ADMA Biologics is scheduled to release its Q2 2025 earnings data on August 6th, with analysts expecting earnings of $0.14 per share and revenue of $121.77 million.
• In its last quarterly report, ADMA Biologics reported a 40.2% increase in revenue year-over-year but missed earnings expectations, reporting $0.14 earnings per share against an anticipated $0.16.
• Recent insider activity includes Director Steve Elms selling nearly 195,000 shares, leading to a 69.04% decrease in his position, while hedge funds continue to increase their stakes in the company.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect ADMA Biologics to post earnings of $0.14 per share and revenue of $121.77 million for the quarter. ADMA Biologics has set its FY 2026 guidance at EPS and its FY 2025 guidance at EPS.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same quarter in the previous year, the business earned $0.08 earnings per share. The company's revenue was up 40.2% on a year-over-year basis. On average, analysts expect ADMA Biologics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Up 1.6%

Shares of NASDAQ:ADMA traded up $0.31 during midday trading on Monday, reaching $19.64. 427,761 shares of the company were exchanged, compared to its average volume of 3,048,427. ADMA Biologics has a fifty-two week low of $10.21 and a fifty-two week high of $25.67. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. The stock has a fifty day simple moving average of $18.81 and a two-hundred day simple moving average of $18.78. The firm has a market cap of $4.69 billion, a PE ratio of 23.14 and a beta of 0.38.

Insider Buying and Selling at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. This trade represents a 69.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,621 shares of company stock worth $9,644,269. Insiders own 3.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of ADMA Biologics by 59.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company's stock valued at $16,201,000 after acquiring an additional 305,064 shares during the period. Royal Bank of Canada grew its position in shares of ADMA Biologics by 112.7% in the 1st quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company's stock valued at $1,903,000 after acquiring an additional 50,801 shares during the period. Finally, Ashton Thomas Private Wealth LLC bought a new stake in shares of ADMA Biologics during the 1st quarter worth about $217,000. Institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

ADMA has been the topic of several recent research reports. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial lifted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.